Varithena for Small Saphenous Vein: Off-Label Use
Yes, using Varithena (polidocanol injectable foam) to occlude the small saphenous vein is off-label. The FDA-approved indication specifically covers only the great saphenous vein (GSV) system, accessory saphenous veins of the GSV system, and visible varicosities of the GSV system above and below the knee 1.
FDA-Approved Indications
The drug label is explicit and limited in scope. Varithena is indicated for:
- Incompetent great saphenous veins
- Accessory saphenous veins (of the GSV system)
- Visible varicosities of the GSV system above and below the knee 1
The small saphenous vein is anatomically distinct from the GSV system and is not mentioned in the approved indications.
Clinical Context
While the FDA approval is restricted to the GSV system, the evidence shows that polidocanol foam has been used for various venous territories in clinical practice:
- One case series documented successful treatment of small saphenous vein reflux with polidocanol endovenous microfoam in complex C3-C6 patients, demonstrating improved symptoms and wound healing 2
- The American Vein and Lymphatic Society position statement supports PEM as safe and effective for C2-C6 disease associated with superficial venous reflux broadly, though this does not change the FDA-approved labeling 3
Important Caveats
Off-label does not mean inappropriate. Many effective treatments in venous disease are used off-label when clinically indicated. However, you must:
- Document the rationale for off-label use in the medical record
- Obtain informed consent that specifically addresses the off-label nature of the treatment
- Verify insurance coverage, as payers may deny reimbursement for off-label indications
- Consider alternative FDA-approved treatments for small saphenous vein insufficiency (thermal ablation, other sclerosants with broader labeling)
The distinction matters primarily for regulatory compliance, medicolegal documentation, and reimbursement—not necessarily for clinical efficacy or safety.